Ischemic and Inflammatory Ocular Adverse Events Following Different Types of Vaccination for COVID-19 and Their Incidence Analysis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the ocular adverse event (OAE) and the incidence rate that can occur after the COVID-19 vaccination. Methods: Patients who visited with an ophthalmologic diagnosis within a month of COVID-19 vaccination were retrospectively analyzed. OAEs were categorized as ischemia and inflammation by their presumed pathogenesis and were compared by types of vaccine: messenger RNA (mRNA) and viral vector vaccine. The crude incidence rate was calculated using data from the Korea Disease Control and Prevention Agency. Results: Twenty-four patients with OAEs after COVID-19 vaccination were reviewed: 10 patients after mRNA and 14 after viral vector vaccine. Retinal vein occlusion (nine patients) and paralytic strabismus (four patients) were the leading diagnoses. Ischemic OAE was likely to occur after viral vector vaccines, while inflammatory OAE was closely related to mRNA vaccine (p = 0.017). The overall incidence rate of OAE was 5.8 cases per million doses: 11.5 per million doses in viral vector vaccine and 3.4 per million doses in mRNA vaccine. Conclusions: OAEs can be observed shortly after the COVID-19 vaccination, and their category was different based on the types of vaccine. The information and incidence
Abstract
Purpose: To evaluate the ocular adverse event (OAE) and the incidence rate that can occur after the COVID-19 vaccination. Methods: Patients who visited with an ophthalmologic diagnosis within a month of COVID-19 vaccination were retrospectively analyzed. OAEs were categorized as ischemia and inflammation by their presumed pathogenesis and were compared by types of vaccine: messenger RNA (mRNA) and viral vector vaccine. The crude incidence rate was calculated using data from the Korea Disease Control and Prevention Agency. Results: Twenty-four patients with OAEs after COVID-19 vaccination were reviewed: 10 patients after mRNA and 14 after viral vector vaccine. Retinal vein occlusion (nine patients) and paralytic strabismus (four patients) were the leading diagnoses. Ischemic OAE was likely to occur after viral vector vaccines, while inflammatory OAE was closely related to mRNA vaccine (p = 0.017). The overall incidence rate of OAE was 5.8 cases per million doses: 11.5 per million doses in viral vector vaccine and 3.4 per million doses in mRNA vaccine. Conclusions: OAEs can be observed shortly after the COVID-19 vaccination, and their category was different based on the types of vaccine. The information and incidence
참고문헌 (44)
- Chagla Z, "The BNT162b2(BioNTech", Pfizer)vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose, 2021, pp.174, JC15~
- Baden LR, "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine", N Engl J Med, 384, pp.403~416 (2021)
- Heath PT, "Safety and efficacy of NVX-CoV2373 COVID-19 vaccine", N Engl J Med, 385, pp.1172~1183 (2021)
- Sadoff J, "Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19", N Engl J Med, 384, pp.2187~2201 (2021)
- Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
- Gao Q, "Development of an inactivated vaccine candidate for SARS-CoV-2", Science, 369, pp.77~81 (2020)
- Xia S, "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1", 2trial, 2021, pp.21, 39~51
- Salah HM, "COVID-19 vaccine and myocarditis", Am J Cardiol, 157, pp.146~148 (2021)
- Hafeez MU, "COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome(TTS) : a systematic review and post hoc analysis", Clin Appl Thromb Hemost, 27, pp.10760296211048815~ (2021)
- Ng XL, "Ocular adverse events after COVID-19 vaccination", Ocul Immunol Inflamm, 29, pp.1216~1224 (2021)
- Eleiwa TK, "Adverse ocular events following COVID-19 vaccination", Inf lamm Res, 70, pp.1005~1009 (2021)
- Wang MT, "COVID-19 vaccination and the eye", Am J Ophthalmol, 240, pp.79~98 (2022)
- Suresh P, "ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis(CVST)", BMJ Case Rep, 14, pp.e243931~ (2021)
- Cines DB, "SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia", N Engl J Med, 384, pp.2254~2256 (2021)
- Palaiodimou L, "Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines : a systematic review and meta-analysis", Neurology, 97, pp.e2136~e2147 (2021)
- Sharifian-Dorche M, "Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19vaccination; a systematic review", J Neurol Sci, 428, pp.117607~ (2021)
- Ichhpujani P, "COVID-19vaccine-associated ocular adverse effects : an overview", Vaccines(Basel), 10, pp.1879~ (2022)
- Choi M, "Vision-threatening ocular adverse events after vaccination against coronavirus disease 2019", J Clin Med, 11, pp.3318~ (2022)
- Park HS, "Retinal hemorrhage after SARS-CoV-2 vaccination", J Clin Med, 10, pp.5705~ (2021)
- von Hundelshausen P, "Vaccine-induced immune thrombotic thrombocytopenia(VITT) : targeting pathomechanisms with Bruton tyrosine kinase inhibitors", Thromb Haemost, 121, pp.1395~1399 (2021)
- Althaus K, "Antibody-induced procoagulant platelets in severe COVID-19 infection", Blood, 137, pp.1061~1071 (2021)
- Datta P, "Platelet factor 4polyanion immune complexes : heparin induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia", Thromb J, 19, pp.66~ (2021)
- Terpos E, "High prevalence of anti-PF4 antibodies following ChAdOx1nCov-19(AZD1222)vaccination even in the absence of thrombotic events", Vaccines(Basel), 9, pp.712~ (2021)
- Huynh A, "Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia", Nature, 596, pp.565~569 (2021)
- Bozkurt B, "Myocarditis with COVID-19mRNA vaccines", Circulation, 144, pp.471~484 (2021)
- Choi S, "Myocarditis-induced sudden death after BNT162b2 mRNA COVID-19 vaccination in Korea : case report focusing on histopathological findings", J Korean Med Sci, 36, pp.e286~ (2021)
- Ouldali N, "Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children : a national post-authorization pharmacovigilance study", Lancet Reg Health Eur, 17, pp.100393~ (2022)
- Singh RB, "Vaccine-associated uveitis after COVID-19 vaccination : vaccine adverse event reporting system database analysis", Ophthalmology, 130, pp.179~186 (2023)
- Tomkins-Netzer O, "Association between vaccination with the BNT162b2 mRNA coronavirus disease 2019 vaccine and noninfectious uveitis : a population-based study", Ophthalmology, 129, pp.1087~1095 (2022)
- Hashimoto Y, "Ocular adverse events after coronavirus disease 2019 mRNA vaccination : matched cohort and self-controlled case series studies using a large database", Ophthalmology, 130, pp.256~264 (2023)
- Rabinovitch T, "Uveitis after the BNT162b2 mRNA vaccination against SARS-CoV-2 infection : a possible association", Retina, 41, pp.2462~2471 (2021)
- Teijaro JR, "COVID-19 vaccines : modes of immune activation and future challenges", Nat Rev Immunol, 21, pp.195~197 (2021)
- Pardi N, "mRNA vaccines : a new era in vaccinology", Nat Rev Drug Discov, 17, pp.261~279 (2018)
- Mucke VT, "First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2 : a case report", BMC Infect Dis, 21, pp.958~ (2021)
- Hakroush S, "Case report : ANCA-associated vasculitis presenting with rhabdomyolysis and pauci-immune crescentic glomerulonephritis after Pfizer-BioNTech COVID-19 mRNA vaccination", Front Immunol, 12, pp.762006~ (2021)
- Greinacher A, "Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination", N Engl J Med, 384, pp.2092~2101 (2021)
- Wack S, "COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease : review of available evidence", J Am Acad Dermatol, 85, pp.1274~1284 (2021)
- Hillman N, "Increased numbers of caveolae in retinal endothelium and pericytes in hypertensive diabetic rats", Eye(Lond), 15(Pt 3), pp.319~325 (2001)
- Martinez-Thompson JM, "Incidence, types, and lifetime risk of adult-onset strabismus", Ophthalmology, 121, pp.877~882 (2014)
- Song P, "Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors", J Glob Health, 9, pp.010427~ (2019)
- Abu Mouch S, "Myocarditis following COVID-19 mRNA vaccination", Vaccine, 39, pp.3790~3793 (2021)
- Klugar M, "Side effects of mRNA-based and viral vector-based COVID-19 vaccines among German healthcare workers", Biology(Basel), 10, pp.752~ (2021)
- Dorney I, "Risk of new retinal vascular occlusion after mRNA COVID-19 vaccination within aggregated electronic health record data", JAMA Ophthalmol, 141, pp.441~447 (2023)
- Roberts HW, "A lack of an association between COVID-19 vaccination and corneal graft rejection : results of a large multi-country population based study", Eye(Lond), 37, pp.2316~2319 (2023)